Exhibit 757 · Press release
SEC Charges Congressman and Others in Insider Trading Scheme (Press Release 2018-151)
Christopher Collins, who served as an independent director of an Australian biotech company, Innate Immunotherapeutics Ltd., is charged with tipping Cameron Collins after receiving confidential information about negative clinical trial results for Innate’s multiple sclerosis drug.
SEC alleges Rep. Christopher Collins (R-NY), an independent director of Innate Immunotherapeutics, learned of negative clinical trial results for the company's MS drug and tipped his son Cameron, who sold shares before the announcement. The information came from his corporate board role, not from his office.
- Source
- U.S. Securities and Exchange Commission
- Date
- 8 August 2018
- Quoted from
- SEC press release 2018-151, 8 Aug 2018, second paragraph
- Grade
- Primary record
- Document
- https://www.sec.gov/news/press-release/2018-151
- Accessed
- 2026-11-09
- Cited by
- Findings citing this exhibit